コンテンツへスキップ
Merck
  • Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach.

Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach.

Urology (2013-12-04)
George T Kedia, Matthias Oelke, Michael Sohn, Markus A Kuczyk, Stefan Ückert
要旨

To elucidate the functional responses of isolated human urethral smooth muscle to various agents known to exert smooth muscle contraction or relaxation. Specimens of penile urethra were obtained from male patients who had undergone male-to-female gender reassignment surgery. Using the tissue bath technique, the contraction induced by increasing concentrations (1 nM-10 μM) of norepinephrine, phenylephrine, acetylcholine, carbachol, prostaglandin F2α, endothelin 1, angiotensin II, and oxytocin was measured. In another set-up, the effects of C-type natriuretic peptide (0.1 nM-1 μM), sodium nitroprusside, sildenafil, forskolin, alpha2-antagonist delquamine, and acetylcholine (1 nM/10 nM-10 μM) on the tension induced by norepinephrine were investigated. The production of cyclic guanosine monophosphate (GMP) and cyclic adenosine monophosphate (AMP) was measured by means of specific radioimmunoassays. Endothelin 1, oxytocin, prostaglandin F2α, norepinephrine, and phenylephrine induced dose-dependent contraction of the isolated urethral tissue, whereas acetylcholine, carbachol, and angiotensin II had no or only minor contractile effects. The contraction induced by norepinephrine was reversed by the drugs with the following rank order of efficacy: sodium nitroprusside > delquamine > sildenafil > C-type natriuretic peptide > forskolin > acetylcholine. The maximal reversion of tension ranged from 68% (sodium nitroprusside) to 22% (acetylcholine). The relaxing effects of the drugs were paralleled by a several-fold increase in tissue levels of cyclic GMP and cyclic adenosine monophosphate. The results provide evidence that urethral smooth muscle is under the control of endogenous compounds, such as adrenergic agonists (norepinephrine and phenylephrine), vasoactive peptides, prostagladins, NO/cyclic GMP, and acetylcholine, assumed to influence micturition at the peripheral level.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(−)-ノルエピネフリン, ≥98%, crystalline
Sigma-Aldrich
(±)-ノルエピネフリン (+)-重酒石酸塩
Sigma-Aldrich
(−)-アデノシン3′5′-サイクリック一リン酸 ナトリウム塩 一水和物, ≥98.0% (HPLC), powder
Sigma-Aldrich
(R)-(−)-フェニレフリン 塩酸塩, powder
Sigma-Aldrich
(−)-アデノシン3′5′-サイクリック一リン酸, ≥98.5% (HPLC), powder
Sigma-Aldrich
オキシトシン, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin)
Sigma-Aldrich
DL-ノルエピネフリン 塩酸塩, crystalline, ≥97% (TLC)
Sigma-Aldrich
オキシトシン
Sigma-Aldrich
オキシトシン 酢酸塩 水和物, ≥97% (HPLC)
Sigma-Aldrich
グアノシン 3′,5′-サイクリック一リン酸, ≥98% (HPLC), powder
Sigma-Aldrich
L-ノルエピネフリン 塩酸塩, ≥98.0% (sum of enantiomers, HPLC)
Supelco
(R)-(−)-フェニレフリン 塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
R-(-)-Phenylephrine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Phenylephrine, European Pharmacopoeia (EP) Reference Standard
(R)-(−)-フェニレフリン 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(R)-(−)-フェニレフリン 塩酸塩, analytical standard